{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"The radiological evaluation based on RECIST v1.1 was assessed using CT scan/PET-CT scan. The DoR was defined as duration from the first documentation of confirmed OR (CR or PR) to date of first progressive disease (PD) or death.","groups":[{"description":"Participants received 0.1 mg/kg of GEN1029 every 2 weeks (Q2W) until the end of treatment.","id":"OG000","title":"Biweekly Regimen (GEN1029 0.1 mg/kg)"},{"description":"Participants received 0.2 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG001","title":"Biweekly Regimen (GEN1029 0.2 mg/kg)"},{"description":"Participants received 0.3 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG002","title":"Biweekly Regimen (GEN1029 0.3 mg/kg)"},{"description":"Participants received 1.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG003","title":"Biweekly Regimen (GEN1029 1.0 mg/kg)"},{"description":"Participants received 2.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG004","title":"Biweekly Regimen (GEN1029 2.0 mg/kg)"},{"description":"Participants received 3.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG005","title":"Biweekly Regimen (GEN1029 3.0 mg/kg)"}],"populationDescription":"Full analysis set included all participants who received at least one dose of GEN1029 and were analyzed according to the actual trial treatment received. Participants who achieved confirmed OR by the investigator assessment were evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 8.8 months (corresponding to maximum observed duration)","title":"Duration of Response (DoR) According to RECIST 1.1","type":"SECONDARY"}